{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:26:03Z","timestamp":1790889963995,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FU356\/12-2"],"award-info":[{"award-number":["FU356\/12-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsche Forschungsgemeinschaft,Germany","award":["RA969\/12-1"],"award-info":[{"award-number":["RA969\/12-1"]}]},{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Introduction of modern cancer therapies has led to increased survival of affected patients. With this advantage, the incidence of cancer therapy-related cardiac dysfunction (CTRCD) has increased and reasonable prevention strategies become necessary. This review outlines the major approaches to limit development and progression of CTRCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>A broad range of cancer therapies can provoke CTRCD ranging from mild asymptomatic forms to severe heart failure. Profound cardiological assessment of cardiovascular comorbidities before initiation of cancer therapy allows identification of cancer patients at higher risk developing CTRCD which may also require closer surveillance. Cardioprotective adjustment of cancer therapy and initiation of cardioprotective medication and lifestyle optimization prior to anti-cancer treatment additionally limit the risk of CTRCD. During therapy, regular examination of cancer patients using high-sensitive cardiological diagnostic tools as three-dimensional (3D) echocardiography and global longitudinal strain (GLS) enables early detection of mild forms of CTRCD. This allows appropriate adjustment of cancer therapy and initiation of CTRCD treatment to prevent further progression to severe forms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Cardiological risk stratification before treatment initiation, cardioprotective interventions before and during cancer therapy, along with regular monitoring of treated cancer patients, can help prevent the development of CTRCD. This maintains the antitumor effects of cancer therapy while limiting cardiotoxic side effects resulting in improved quality of life and mortality of affected cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11897-025-00697-x","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:06:39Z","timestamp":1739945199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prevention of cancer-therapy related cardiac dysfunction"],"prefix":"10.1007","volume":"22","author":[{"given":"Elias","family":"Haj-Yehia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca I.","family":"Mincu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Totzeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"3","key":"697_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"697_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41591-022-01746-x","volume":"28","author":"RC Fitzgerald","year":"2022","unstructured":"Fitzgerald RC, et al. The future of early cancer detection. Nat Med. 2022;28(4):666\u201377.","journal-title":"Nat Med"},{"issue":"11","key":"697_CR3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/cncr.34743","volume":"129","author":"A Desai","year":"2023","unstructured":"Desai A, Reddy NK, Subbiah V. Top advances of the year: precision oncology. Cancer. 2023;129(11):1634\u201342.","journal-title":"Cancer"},{"issue":"41","key":"697_CR4","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"3","key":"697_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/eurjcn\/zvab057","volume":"21","author":"Y Koop","year":"2022","unstructured":"Koop Y, et al. Quality of life in breast cancer patients with cancer treatment-related cardiac dysfunction: a qualitative study. Eur J Cardiovasc Nurs. 2022;21(3):235\u201342.","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"2","key":"697_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000521680","volume":"147","author":"KD Boudoulas","year":"2022","unstructured":"Boudoulas KD, et al. Cardiovascular disease, cancer, and multimorbidity interactions: clinical implications. Cardiology. 2022;147(2):196\u2013206.","journal-title":"Cardiology"},{"key":"697_CR7","doi-asserted-by":"publisher","first-page":"753313","DOI":"10.3389\/fcvm.2021.753313","volume":"8","author":"H Xiao","year":"2021","unstructured":"Xiao H, et al. Advances in biomarkers for detecting early cancer treatment-related cardiac dysfunction. Front Cardiovasc Med. 2021;8:753313.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"697_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10741-018-9675-2","volume":"23","author":"R Moudgil","year":"2018","unstructured":"Moudgil R, Parekh PA. Biomarkers in cancer therapy related cardiac dysfunction (CTRCD). Heart Fail Rev. 2018;23(2):255\u20139.","journal-title":"Heart Fail Rev"},{"issue":"3","key":"697_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaccao.2021.06.007","volume":"3","author":"C Bergom","year":"2021","unstructured":"Bergom C, et al. Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification. JACC CardioOncol. 2021;3(3):343\u201359.","journal-title":"JACC CardioOncol"},{"issue":"3","key":"697_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","volume":"3","author":"JD Mitchell","year":"2021","unstructured":"Mitchell JD, et al. Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the international cardio-oncology society. JACC CardioOncol. 2021;3(3):360\u201380.","journal-title":"JACC CardioOncol"},{"issue":"3","key":"697_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","volume":"34","author":"FA van Nimwegen","year":"2016","unstructured":"van Nimwegen FA, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of hodgkin lymphoma. J Clin Oncol. 2016;34(3):235\u201343.","journal-title":"J Clin Oncol"},{"issue":"11","key":"697_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987\u201398.","journal-title":"N Engl J Med"},{"issue":"3","key":"697_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jaccao.2021.07.008","volume":"3","author":"LE Carlson","year":"2021","unstructured":"Carlson LE, et al. Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE study. JACC CardioOncol. 2021;3(3):381\u201392.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"697_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ejh.13482","volume":"106","author":"R Alblooshi","year":"2021","unstructured":"Alblooshi R, et al. Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. Eur J Haematol. 2021;106(1):32\u20139.","journal-title":"Eur J Haematol"},{"issue":"2","key":"697_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","volume":"3","author":"R Dulery","year":"2021","unstructured":"Dulery R, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol. 2021;3(2):250\u20139.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"697_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63\u201375.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"697_CR17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/eurjhf\/hft008","volume":"15","author":"CG Tocchetti","year":"2013","unstructured":"Tocchetti CG, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013;15(5):482\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"697_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s11864-021-00924-2","volume":"23","author":"N Mukunda","year":"2022","unstructured":"Mukunda N, et al. Cardiotoxicity of Systemic Melanoma Treatments. Curr Treat Options Oncol. 2022;23(2):240\u201353.","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"697_CR19","doi-asserted-by":"publisher","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","volume":"2","author":"RI Mincu","year":"2019","unstructured":"Mincu RI, et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8):e198890.","journal-title":"JAMA Netw Open"},{"key":"697_CR20","first-page":"100420","volume":"25","author":"L Michel","year":"2019","unstructured":"Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019;25:100420.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"1","key":"697_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey N, et al. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21\u201336.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"697_CR22","doi-asserted-by":"publisher","first-page":"101536","DOI":"10.1016\/j.cpcardiol.2022.101536","volume":"48","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, et al. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy. Curr Probl Cardiol. 2023;48(3):101536.","journal-title":"Curr Probl Cardiol"},{"issue":"2","key":"697_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hon.2959","volume":"40","author":"A Das","year":"2022","unstructured":"Das A, et al. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials. Hematol Oncol. 2022;40(2):233\u201342.","journal-title":"Hematol Oncol"},{"issue":"3","key":"697_CR24","first-page":"66","volume":"9","author":"A Briasoulis","year":"2022","unstructured":"Briasoulis A, et al. Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents. J Cardiovasc Dev Dis. 2022;9(3):66.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"20","key":"697_CR25","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","volume":"43","author":"M Totzeck","year":"2022","unstructured":"Totzeck M, et al. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J. 2022;43(20):1928\u201340.","journal-title":"Eur Heart J"},{"issue":"37","key":"697_CR26","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"4","key":"697_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399.","journal-title":"Eur Heart J"},{"issue":"4","key":"697_CR28","first-page":"355","volume":"13","author":"A Denegri","year":"2016","unstructured":"Denegri A, et al. Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol. 2016;13(4):355\u201363.","journal-title":"J Geriatr Cardiol"},{"key":"697_CR29","doi-asserted-by":"publisher","first-page":"1062858","DOI":"10.3389\/fcvm.2022.1062858","volume":"9","author":"M Torrente","year":"2022","unstructured":"Torrente M, et al. Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. Front Cardiovasc Med. 2022;9:1062858.","journal-title":"Front Cardiovasc Med"},{"issue":"Suppl 2","key":"697_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1047951115000906","volume":"25","author":"VI Franco","year":"2015","unstructured":"Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines. Cardiol Young. 2015;25(Suppl 2):107\u201316.","journal-title":"Cardiol Young"},{"issue":"11","key":"697_CR31","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104\u201314.","journal-title":"Circulation"},{"issue":"34","key":"697_CR32","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"6","key":"697_CR33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","volume":"21","author":"C Mueller","year":"2019","unstructured":"Mueller C, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715\u201331.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"697_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijcard.2009.09.564","volume":"148","author":"M Feola","year":"2011","unstructured":"Feola M, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol. 2011;148(2):194\u20138.","journal-title":"Int J Cardiol"},{"issue":"2","key":"697_CR35","doi-asserted-by":"publisher","first-page":"e014708","DOI":"10.1161\/JAHA.119.014708","volume":"9","author":"BG Demissei","year":"2020","unstructured":"Demissei BG, et al. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. J Am Heart Assoc. 2020;9(2):e014708.","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"697_CR36","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910\u20136.","journal-title":"J Clin Oncol"},{"key":"697_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00392-023-02327-9","volume":"113","author":"E Haj-Yehia","year":"2024","unstructured":"Haj-Yehia E, Mincu RI, Korste S, Lampe L, Margraf SM, Michel L, Mahabadi AA, Ferdinandy P, Rassaf T, Totzeck M. High neutrophil-to-lymphocyte ratio is associatedrelated cardiovascular toxicity in high-risk cancer patients under immune checkpoint inhibitor therapy. Clin Res Cardiol. 2024;113:301\u201312.","journal-title":"Clin Res Cardiol."},{"issue":"9","key":"697_CR38","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","volume":"61","author":"M Putt","year":"2015","unstructured":"Putt M, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 2015;61(9):1164\u201372.","journal-title":"Clin Chem"},{"issue":"8","key":"697_CR39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"697_CR40","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/CIRCRESAHA.116.309004","volume":"119","author":"LA Beer","year":"2016","unstructured":"Beer LA, et al. Baseline immunoglobulin E levels as a marker of doxorubicin- and trastuzumab-associated cardiac dysfunction. Circ Res. 2016;119(10):1135\u201344.","journal-title":"Circ Res"},{"issue":"2","key":"697_CR41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jaccao.2022.03.004","volume":"4","author":"NML Battisti","year":"2022","unstructured":"Battisti NML, et al. Prevalence of cardiovascular disease in patients with potentially curable malignancies: a national registry dataset analysis. JACC CardioOncol. 2022;4(2):238\u201353.","journal-title":"JACC CardioOncol"},{"issue":"19","key":"697_CR42","doi-asserted-by":"publisher","first-page":"e029465","DOI":"10.1161\/JAHA.123.029465","volume":"12","author":"AF Yu","year":"2023","unstructured":"Yu AF, et al. Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Am Heart Assoc. 2023;12(19):e029465.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"697_CR43","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bcp.13008","volume":"82","author":"F Aminkeng","year":"2016","unstructured":"Aminkeng F, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82(3):683\u201395.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"697_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","volume":"140","author":"P Garcia-Pavia","year":"2019","unstructured":"Garcia-Pavia P, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019;140(1):31\u201341.","journal-title":"Circulation"},{"issue":"9","key":"697_CR45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ng.3374","volume":"47","author":"F Aminkeng","year":"2015","unstructured":"Aminkeng F, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015;47(9):1079\u201384.","journal-title":"Nat Genet"},{"issue":"13","key":"697_CR46","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","volume":"30","author":"JG Blanco","year":"2012","unstructured":"Blanco JG, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2013a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30(13):1415\u201321.","journal-title":"J Clin Oncol"},{"issue":"24","key":"697_CR47","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","volume":"112","author":"L Wojnowski","year":"2005","unstructured":"Wojnowski L, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112(24):3754\u201362.","journal-title":"Circulation"},{"issue":"18","key":"697_CR48","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"4","key":"697_CR49","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","volume":"65","author":"J Shapira","year":"1990","unstructured":"Shapira J, et al. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen A prospective randomized evaluation. Cancer. 1990;65(4):870\u20133.","journal-title":"Cancer"},{"issue":"23","key":"697_CR50","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"697_CR51","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71(20):2281\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"697_CR52","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"D Cardinale","year":"2018","unstructured":"Cardinale D, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126\u201337.","journal-title":"Eur J Cancer"},{"issue":"21","key":"697_CR53","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671\u201380.","journal-title":"Eur Heart J"},{"key":"697_CR54","doi-asserted-by":"publisher","first-page":"e006513","DOI":"10.1161\/JAHA.117.006513","volume":"6","author":"G Gulati","year":"2017","unstructured":"Gulati G, Heck SL, R\u00f8sj\u00f8 H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T. Neurohormonal blockade anCardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (Prevention of Cardiac Dysfunction DCancer Therapy) Study. J Am Heart Assoc. 2017;6:e006513.","journal-title":"J Am Heart Assoc."},{"issue":"22","key":"697_CR55","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73(22):2859\u201368.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"697_CR56","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol. 2016;2(8):1030\u20137.","journal-title":"JAMA Oncol"},{"issue":"1","key":"697_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2015","unstructured":"Akpek M, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"697_CR58","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/ph15020151","volume":"15","author":"Y Morofuji","year":"2022","unstructured":"Morofuji Y, et al. Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals (Basel). 2022;15(2):151.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"697_CR59","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/10428194.2024.2317343","volume":"65","author":"R Nemec","year":"2024","unstructured":"Nemec R, et al. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP. Leuk Lymphoma. 2024;65(6):783\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"697_CR60","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","volume":"58","author":"Z Acar","year":"2011","unstructured":"Acar Z, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"697_CR61","first-page":"1638","volume":"39","author":"I Alfaris","year":"2023","unstructured":"Alfaris I, et al. Sodium-Glucose Cotransporter 2 Inhibitor Among Patients With Cancer Therapy-Induced Left Ventricular Dysfunction. Can J Cardiol. 2023;39(11):1638\u201341.","journal-title":"Can J Cardiol"},{"issue":"8","key":"697_CR62","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","volume":"10","author":"CA Gongora","year":"2022","unstructured":"Gongora CA, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022;10(8):559\u201367.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"697_CR63","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/jgh.16498","volume":"39","author":"CH Chiang","year":"2024","unstructured":"Chiang CH, et al. The impact of sodium-glucose cotransporter-2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer. J Gastroenterol Hepatol. 2024;39(5):902\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"697_CR64","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","volume":"60","author":"H Tang","year":"2017","unstructured":"Tang H, et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60(10):1862\u201372.","journal-title":"Diabetologia"},{"issue":"8","key":"697_CR65","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/dom.13745","volume":"21","author":"I Dicembrini","year":"2019","unstructured":"Dicembrini I, et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2019;21(8):1871\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"697_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","volume":"5","author":"D De Ruysscher","year":"2019","unstructured":"De Ruysscher D, et al. Radiotherapy toxicity. Nat Rev Dis Primers. 2019;5(1):13.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"697_CR67","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nrc2288","volume":"7","author":"D Verellen","year":"2007","unstructured":"Verellen D, et al. Innovations in image-guided radiotherapy. Nat Rev Cancer. 2007;7(12):949\u201360.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"697_CR68","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","volume":"16","author":"K Banfill","year":"2021","unstructured":"Banfill K, et al. Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions. J Thorac Oncol. 2021;16(2):216\u201327.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"697_CR69","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jamaoncol.2020.7468","volume":"7","author":"I Meattini","year":"2021","unstructured":"Meattini I, et al. Association of breast cancer irradiation with cardiac toxic effects: a narrative review. JAMA Oncol. 2021;7(6):924\u201332.","journal-title":"JAMA Oncol"},{"issue":"4","key":"697_CR70","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997;15(4):1333\u201340.","journal-title":"J Clin Oncol"},{"issue":"1","key":"697_CR71","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","volume":"1","author":"AVS Macedo","year":"2019","unstructured":"Macedo AVS, et al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncol. 2019;1(1):68\u201379.","journal-title":"JACC CardioOncol"},{"key":"697_CR72","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1186\/1471-2407-14-842","volume":"14","author":"S Deng","year":"2014","unstructured":"Deng S, et al. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer. 2014;14:842.","journal-title":"BMC Cancer"},{"issue":"4","key":"697_CR73","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3390\/jcm9040896","volume":"9","author":"R Kikuchi","year":"2020","unstructured":"Kikuchi R, Shah NP, Dent SF. Strategies to prevent cardiovascular toxicity in breast cancer: is it ready for primetime. J Clin Med. 2020;9(4):896.","journal-title":"J Clin Med"},{"issue":"9","key":"697_CR74","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"697_CR75","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","volume":"51","author":"N Yamaguchi","year":"2015","unstructured":"Yamaguchi N, et al. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer. 2015;51(16):2314\u201320.","journal-title":"Eur J Cancer"},{"issue":"12","key":"697_CR76","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","volume":"24","author":"DN Waterhouse","year":"2001","unstructured":"Waterhouse DN, et al. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf. 2001;24(12):903\u201320.","journal-title":"Drug Saf"},{"issue":"21","key":"697_CR77","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","volume":"139","author":"SC Gilchrist","year":"2019","unstructured":"Gilchrist SC, et al. cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the american heart association. Circulation. 2019;139(21):e997\u20131012.","journal-title":"Circulation"},{"issue":"6","key":"697_CR78","first-page":"1727","volume":"26","author":"S Abo","year":"2018","unstructured":"Abo S, et al. A hospital and home-based exercise program to address functional decline in people following allogeneic stem cell transplantation. Support Care Cancer. 2018;26(6):1727\u201336.","journal-title":"Support Care Cancer"},{"issue":"3","key":"697_CR79","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11912-018-0681-2","volume":"20","author":"RW Squires","year":"2018","unstructured":"Squires RW, Shultz AM, Herrmann J. Exercise training and cardiovascular health in cancer patients. Curr Oncol Rep. 2018;20(3):27.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"697_CR80","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/2047487319874900","volume":"28","author":"F D'Ascenzi","year":"2021","unstructured":"D\u2019Ascenzi F, et al. The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology. Eur J Prev Cardiol. 2021;28(7):725\u201335.","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"697_CR81","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.117.024671","volume":"137","author":"JM Scott","year":"2018","unstructured":"Scott JM, et al. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137(11):1176\u201391.","journal-title":"Circulation"},{"issue":"3","key":"697_CR82","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/eurjpc\/zwab006","volume":"29","author":"J Murray","year":"2022","unstructured":"Murray J, et al. The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review. Eur J Prev Cardiol. 2022;29(3):463\u201372.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"697_CR83","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"39","key":"697_CR84","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"33","key":"697_CR85","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"11","key":"697_CR86","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"697_CR87","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J Celutkiene","year":"2020","unstructured":"Celutkiene J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(9):1504\u201324.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"697_CR88","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","volume":"11","author":"JC Plana","year":"2018","unstructured":"Plana JC, et al. Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient. JACC Cardiovasc Imaging. 2018;11(8):1173\u201386.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"697_CR89","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","volume":"18","author":"M Galderisi","year":"2017","unstructured":"Galderisi M, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18(12):1301\u201310.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"697_CR90","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jcmg.2018.01.015","volume":"11","author":"KW Zhang","year":"2018","unstructured":"Zhang KW, et al. Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction. JACC Cardiovasc Imaging. 2018;11(8):1059\u201368.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"697_CR91","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/ehjci\/jex033","volume":"18","author":"C Santoro","year":"2017","unstructured":"Santoro C, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017;18(8):930\u20136.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"10","key":"697_CR92","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","volume":"4","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou EK, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol. 2019;4(10):1007\u201318.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"697_CR93","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel L, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22(2):350\u201361.","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 35","key":"697_CR94","doi-asserted-by":"publisher","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","volume":"10","author":"L Michel","year":"2018","unstructured":"Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018;10(Suppl 35):S4282\u201395.","journal-title":"J Thorac Dis"},{"issue":"1","key":"697_CR95","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaccao.2023.10.008","volume":"6","author":"A Mecinaj","year":"2024","unstructured":"Mecinaj A, et al. Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction. JACC CardioOncology. 2024;6(1):83\u201395.","journal-title":"JACC CardioOncology"},{"issue":"2","key":"697_CR96","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171\u201390.","journal-title":"Ann Oncol"},{"issue":"11","key":"697_CR97","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.21037\/tcr-20-1869","volume":"9","author":"H Dong","year":"2020","unstructured":"Dong H, et al. Can ACEI\/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?-a meta-analysis of randomized controlled trials. Transl Cancer Res. 2020;9(11):7034\u201343.","journal-title":"Transl Cancer Res"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00697-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-025-00697-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00697-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:01:49Z","timestamp":1768550509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-025-00697-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1007\/s11897-025-00697-x","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"E.H.-Y. reports personal fees and others from AstraZeneca, which are outside the submitted work. L.M. reports personal fees from Bayer, Alnylam, AstraZeneca, IFFM e. V. and from Bund der Niedergelassenen Kardiologen (BNK), which are outside the submitted work. M.T. and T.R. report personal fees and others from Edwards and Novartis, Bristol Myers Squibb, Bayer, Daiichi Sankyo and Astra Zeneca, which are outside the submitted work. T.R. cofounded Bimyo, a company focusing on the development of cardioprotective peptides. All other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"9"}}